Home Featured Page 142

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

PT353 – Dr. James Fadiman, Dr. Sam Gandy, & Dr. David...

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alochol...

Psychedelic Research Bulletin: July and August 2022

Wesana Announces Sale of Clinic Management Services Organization

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its...

Looking Forward to Horizons Northwest, This September in Portland

COMPASS Pathways to participate in three upcoming investor events

1...141142143...296 Page 142 of 296

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

PT353 – Dr. James Fadiman, Dr. Sam Gandy, & Dr. David...

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alochol...

Psychedelic Research Bulletin: July and August 2022

Wesana Announces Sale of Clinic Management Services Organization

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its...

Looking Forward to Horizons Northwest, This September in Portland

Looking Forward to Horizons Northwest, This September in Portland

COMPASS Pathways to participate in three upcoming investor events

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY